According to CoinMeta, AngliCon announced that the company has signed a comprehensive cooperation agreement on innovative drugs and delivery systems with Suzhou Ruizhijie and MicroX. Cooperation will be carried out on three innovative drug pipelines, with a total pre-clinical research and development budget of approximately 89.5 million yuan. It is expected that this year, there will be an additional investment of about 20.5 million yuan in research and development for the PCC phase.